News

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

According to the company, AURN001 is the first allogeneic cell therapy to receive both FDA designations for the treatment of corneal edema secondary to corneal endothelial disease.

Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.

Investigators looked to see if a large language model could provide safe, accurate, and readable information to patient inquiries about cataract surgery.

According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration.

This Los Angeles-based ophthalmologist and medical creator discusses the role of social media in combating misinformation and building health care practices.

The Type A meeting addressed questions the FDA had about the late-stage product candidate

Proactive communication and leveraging advanced, yet reliable, technologies  to maximize efficiency are essential pillars of success.

We stand on the cusp of a new era in vitreoretinal surgery, one that has been marked by only a select few seminal innovations

Three approaches to examination provide a comprehensive overview

The retrospective real-world evaluation of the drug considered several important as-yet-unanswered questions

A key distinction between patients seen in the clinic vs those enrolled in clinical trials has to do with characteristics dictated by the trial’s inclusion/exclusion criteria.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

XLRP often leads to blindness by middle age with no treatment options currently available

To date, only the onset and enlargement of hyperTDs measured using en-face OCT imaging has been validated as a clinical trial endpoint.

Shift in the understanding of TED has led to a reevaluation of the Rundle curve

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss how isolated empty sella is not a sign of elevated ICP

The mapping method revealed prominent microscopic abnormalities consistent with diabetic retinopathy.

The company highlighted successful enrollment in the SOL-1 Phase 3 trial for wet AMD, plans for a new repeat dosing study (SOL-R), and positive 48-week data from the Phase 1 HELIOS study for NPDR

The mapping method revealed prominent microscopic abnormalities consistent with DR

Under the new policy, grant-making entities will be encouraged to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials.

Investigators say the discovery highlights the importance of genetic consultation

The mapping method revealed prominent microscopic abnormalities consistent with DR